Alterity Therapeutics Announces Appointment of Ann Cunningham to Board of Directors

Alterity Therapeutics Limited filed a Form 6-K on April 21, 2026, to report an Initial Director's Interest Notice for Ann Cunningham. Ms. Cunningham was appointed as a director of the company effective April 17, 2026. According to the filing, which serves as an Appendix 3X under ASX listing rules, Ms. Cunningham does not currently hold any registered or indirect interests in the securities of the company, nor does she have any interests in contracts related to the company's securities at the time of her appointment. Alterity Therapeutics is a development-stage enterprise headquartered in Melbourne, Australia. The report was signed by Chairman Julian Babarczy and is incorporated by reference into several of the company's existing Registration Statements on Form S-8 and Form F-3. No other corporate updates or clinical trial data were disclosed in this filing.